Cardiff Oncology第四季度GAAP每股收益$(0.21)优于预期$(0.24),销售额$151.00K优于预期$94.17K

财报速递
28 Feb
Cardiff Oncology(纳斯达克股票代码:CRDF)报告季度每股亏损$(0.21),优于分析师一致预期的$(0.24),增长了12.5%。与去年同期持平。公司报告季度销售额为$151.00千,优于分析师一致预期的$94.17千,增长了60.35%。与去年同期的销售额$156.00千相比下降了3.21%。

以上内容来自Benzinga Earnings专栏,原文如下:

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 12.5 percent. This is unchanged from the same period last year. The company reported quarterly sales of $151.00 thousand which beat the analyst consensus estimate of $94.17 thousand by 60.35 percent. This is a 3.21 percent decrease over sales of $156.00 thousand the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10